Liquid Biopsy Market Report, By Type of Cell Therapy (Autologous, Allogeneic); Application (Oncology, Cardiovascular Disorders, Musculoskeletal Disorders, etc.); By Cell Source (Stem Cell-Based, Non-Stem Cell-Based); By End-Users (Hospitals & Clinics, Research Institutes, Biotechnology and Pharmaceutical Companies); and Regions 2024-2032

Market Overview:

"The global liquid biopsy market was valued at US$ 13.95 Billion in 2023, and is expected to register a CAGR of 7.6% over the forecast period and reach US$ 26.9 Bn in 2032."

Report Attributes	Details
Base Year	2023
Forecast Years	2024-2032
Historical Years	2021-2023
Market Growth Rate (2024-2032)	7.6%

Liquid biopsy is a laboratory test conducted on a sample of blood, urine, or other body fluid to identify and detect cancer cells from a tumor or small pieces of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA), or by using other molecules released by tumor cells into fluids in the body of a person. It is a simple and minimally-invasive alternative to surgical and traditional tissue biopsies and has emerged as a revolutionary diagnostic approach, offering real-time detection of biomarkers in bodily fluids, primarily blood.

Various technologies such as Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and digital PCR play pivotal roles in liquid biopsy, enabling the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles. Liquid biopsy facilitate early cancer detection, monitoring treatment response, and tracking disease progression, among others.

Market growth continues to be supported by significant advancements in recent years, with a surge in research and development efforts and companies offering comprehensive solutions and services, ranging from sample collection to data analysis, enhancing the overall efficiency of liquid biopsy procedures. The benefits of liquid biopsy include its ability to capture tumor heterogeneity, detect minimal residual disease, and monitor treatment resistance. The advantages of early cancer detection and personalized treatment strategies further highlight the growing importance of liquid biopsy in oncology.

Some key trends in the liquid biopsy market include the integration of Artificial Intelligence (AI) for data interpretation, expansion of applications beyond oncology, and the development of Point-Of-Care Testing (POCT) solutions. Key developments in the include the introduction of multiomics approaches, novel biomarker discovery, and the continuous refinement of liquid biopsy technologies to improve sensitivity and specificity.

Liquid Biopsy Market Trends and Drivers

Key factors driving increasing traction of liquid biopsies and further advancements is the non-invasiveness of the tests, offering patients a less intrusive and uncomfortable alternative to traditional tissue biopsies. It also promotes early detection and monitoring of diseases, and the rising prevalence of cancers and need for effective, real-time monitoring is contributing significantly to increasing demand for liquid biopsy technologies. Also, expanding applications beyond oncology, such as in prenatal testing and organ transplant monitoring, have broadened market scope, and this is another key factor supporting revenue growth of the market.

Moreover, advancements in technology, particularly in next-generation sequencing and digital PCR, enhance the sensitivity and specificity of liquid biopsy, reinforcing its reliability for clinical use. The steadily growing trend of precision medicine and personalized treatment strategies further highlights the importance of liquid biopsy in tailoring therapies to individual patient profiles, and continues to position it as a transformative approach in the field of diagnostics and disease management.

Liquid Biopsy Market Restraining Factors

Despite its promising potential, the adoption of liquid biopsy faces several constraints to wider use. The high cost associated with liquid biopsy procedures and technologies poses a significant barrier, limiting accessibility for a broader patient population. Also, challenges related to accessibility of liquid biopsies in general populations and underserved populations is limiting those communities that could benefit most from this approach.

The current regulatory landscape and the need for validation of liquid biopsy assays also contribute to a slow and cautious adoption process. Concerns regarding the sensitivity and specificity of liquid biopsy results, especially in comparison to traditional tissue biopsies, is another factor supporting some skepticism among healthcare providers.

Other negative trends include challenges related to standardization of liquid biopsy protocols and the need for robust clinical evidence to establish its efficacy. In addition, reimbursement issues and a lack of awareness among healthcare professionals and patients about the benefits of liquid biopsy contribute to restraining market potential.

Liquid Biopsy Market Opportunities

Leading companies in the global liquid biopsy market can focus on aiding in initiatives in the direction of expanding liquid biopsy applications beyond oncology. Liquid biopsy is increasingly being explored for prenatal testing, infectious disease monitoring, and organ transplant rejection detection, broadening the scope of potential applications. Also, technological advancements present a significant opportunity for companies to innovate and enhance the sensitivity and specificity of liquid biopsy assays. Investing in research and development to improve technologies such as next-generation sequencing and digital PCR can further enable companies gain an advantage and strengthen market position.

In addition, the rising trend of precision medicine and personalized treatment creates demand for liquid biopsy in tailoring therapies to individual patient profiles, offering a substantial market opportunity. Moreover, strategic collaborations with healthcare providers and diagnostic laboratories can facilitate the integration of liquid biopsy into routine clinical practice, and create revenue avenues for growth. Furthermore, addressing cost concerns and easing the affordability and accessibility of liquid biopsy procedures by working towards achieving reimbursement approvals can unlock accessibility to larger market share.

Liquid Biopsy Market Segmentation

By Sample Type

• Blood-based Liquid Biopsy
• Urine-based Liquid Biopsy
• Saliva-based Liquid Biopsy
• Cerebrospinal Fluid-based Liquid Biopsy

The blood-based liquid biopsy segment is expected to dominate the other sample type segments in terms of revenue share. This is attributed to its widespread adoption owing to the convenience of blood sample collection, minimally invasive nature, and ability to capture a diverse range of biomarkers, including circulating tumor DNA and circulating tumor cells.

By Biomarker Type

• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Extracellular Vesicles (EVs)
• Other Biomarkers

The circulating tumor DNA segment is expected to account for largest revenue share owing to the role ctDNA plays as a comprehensive biomarker, reflecting tumor heterogeneity and providing insights into cancer mutations. Increasing applications in oncology, including early detection and monitoring treatment response, highlights its significance, and as the prominence of liquid biopsy increases, adoption of ctDNA is expected to incline in parallel owing to its versatility and broad applicability.

By Application

• Oncology
• Infectious Disease Testing
• Prenatal Testing
• Transplant Rejection Monitoring

Among the application segments, the oncology segment is projected to account for the largest revenue share over the forecast period. This is attributed to the rising prevalence of cancer globally and increasing adoption of liquid biopsy for early cancer detection, treatment monitoring, and recurrence surveillance. The ability of liquid biopsy to capture circulating tumor DNA and circulating tumor cells makes it a valuable tool in the oncology landscape.

By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies

The hospitals and clinics segment is expected to account for largest revenue share over the forecast period, supported by increasing integration of liquid biopsy into routine clinical practice for cancer diagnosis and monitoring. Hospitals and clinics serve as primary points of patient care, allowing seamless incorporation of liquid biopsy technologies into existing diagnostic workflows. With a growing emphasis on early cancer detection and personalized treatment, adoption of liquid biopsy in clinical settings is expected to continue to increase and drive revenue growth of the hospital and clinic segment.

By Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Poland
• Benelux
• Nordic
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

The global liquid biopsy market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America has been a prominent player in the global liquid biopsy market, driven by the presence of key market players, significant investments in healthcare infrastructure, and a strong emphasis on research and development. In Europe, countries such as Germany, the UK, and France have registered substantial growth, while growth of the market in Asia Pacific is driven significantly by inclining adoption rate of liquid biopsy due to rising prevalence of cancer and a growing focus on advanced diagnostic technologies in countries such as China and Japan.

Some common factors driving growth of the major regional liquid biopsy markets include increasing prevalence of cancer, technological advancements in liquid biopsy techniques, and a growing trend toward personalized medicine and precision diagnostics.

Leading Companies in Liquid Biopsy Market & Competitive Landscape:

The competitive landscape in the liquid biopsy market is dynamic, with several leading companies adopting various strategies to maintain their positions and expand consumer base. Key players, such as Guardant Health, Roche Diagnostics, and Bio-Rad Laboratories, are investing significantly in research and development to innovate and enhance the sensitivity and specificity of liquid biopsy technologies. Strategic collaborations and partnerships between companies, academic institutions, and healthcare providers are common, enabling access to diverse expertise and expanding market reach. Companies focused on innovations in liquid biopsy are developing platforms that are changing how cancer is detected, and also entering into collaborations with pharmaceutical and biotechnology companies to provide anonymized clinical information and genomic data derived from their liquid biopsy tests. These alliances provide drug developers with valuable insights into tumor evolution, treatment resistance, and the efficacy of anti-cancer therapies.

In addition, mergers and acquisitions play a major role in consolidating market presence, with companies acquiring innovative technologies or complementary services to strengthen their portfolios. Focused marketing initiatives and educational campaigns are employed to raise awareness among healthcare professionals and patients about the benefits of liquid biopsy, aiming to drive broader adoption.

These companies include:

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• BIOCEPT, INC.
• Bio-Rad Laboratories, Inc.
• Exact Science Corporation
• Menarini Silicon Biosystems
• Epic Sciences
• NeoGenomics Laboratories
• Mdxhealth
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Oncocyte Corporation
• Johnson & Johnson Services, Inc.
• PathAI
• Fluxion Biosciences Inc.

Recent Development:

January 2024: Veracyte officially agreed to acquire C2i Genomics, marking an expansion of its diagnostic platform to incorporate whole-genome Minimal Residual Disease (MRD) detection capabilities through cell-free DNA (cfDNA) in liquid biopsies. C2i's MRD solution, which necessitates minimal blood (as little as 3–4 mL blood or 1–2 mL plasma), boasts a rapid turnaround time of just two weeks, outperforming imaging and other molecular tests. The MRD testing by C2i utilizes Artificial Intelligence (AI) to construct circulating tumor DNA signatures, comparing the genomics of the patient's tumor and blood, thereby eliminating the necessity for custom biomarker panels. This strategic move enhances Veracyte's diagnostic capabilities in the evolving landscape of liquid biopsy technologies.

November 2023: Syantra, which is an innovation company specializing in the development of novel methods for cancer detection through its liquid biopsy platform, has expanded its intellectual property portfolio. Also, the company has entered into a strategic collaboration with Limmi, which is a US-based technology firm utilizing AI-driven insights for advanced disease detection and management techniques. This development signifies a notable milestone for Syantra and reflects significant progress in comprehending human diseases. The recently disclosed partnership with Limmi introduces a scalable AI-powered platform, augmenting Syantra's capacity to derive innovative insights from clinical data and ultimately improving its capability to detect various cancers in their early stages.

September 2023: Biocept announced signing of a non-exclusive licensing agreement for its CNSide liquid biopsy assay with Plus Therapeutics, expanding upon their existing 2022 laboratory services agreement. Plus Therapeutics is incorporating CNSide in a clinical trial evaluating its targeted radiotherapeutic rhenium 186 obisbemeda for patients with carcinomas or melanomas suspected of Leptomeningeal Metastases (LM). The new agreement allows Plus to conduct CNSide testing during clinical trials and potentially for commercial use, contingent upon regulatory approval. Biocept is providing expertise, including equipment and material sourcing consultation, along with the necessary technology and training for the assay.

Liquid Biopsy Market Research Scope

Report Metric	Report Details
Market size available for the years	2021-2023
Base Year	2023
Forecast Period	2024-2032
Compound Annual Growth Rate (CAGR)	7.6%
Segment covered	Sample Type, Biomarker Type, Application, End-user
Regions Covered	North America:  The U.S. & Canada Latin America: Brazil, Mexico, Argentina, & Rest of Latin America Asia Pacific: China, India, Japan, Australia & New Zealand, ASEAN, & Rest of Asia Pacific Europe: Germany, The U.K., France, Spain, Italy, Russia, Poland, BENELUX, NORDIC, & Rest of Europe The Middle East & Africa: Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, and Rest of MEA
Fastest Growing Country in Europe	UK
Largest Market	North America
Key Players	Thermo Fisher Scientific Inc., Illumina, Inc., BIOCEPT, INC., Bio-Rad Laboratories, Inc., Exact Science Corporation, Menarini Silicon Biosystems, Epic Sciences, NeoGenomics Laboratories, mdxhealth, F. Hoffmann-La Roche Ltd., QIAGEN, Oncocyte Corporation, Johnson & Johnson Services, Inc., PathAI. Fluxion Biosciences Inc.